摘要
目的:探讨缬沙坦联合特拉唑嗪治疗顽固性高血压的应用效果。方法:选取2019年3月-2020年12月笔者所在医院接收的顽固性高血压患者78例,收集其相关临床资料开展本研究,依据用药方案的差异进行分组。两组均采用常规治疗,对照组同时采用缬沙坦治疗,研究组应用缬沙坦联合特拉唑嗪治疗。对比两组患者临床治疗效果、两组血压水平、血管内皮功能、肱动脉直径水平及不良反应。结果:研究组治疗有效率高于对照组(P<0.05);干预前两组患者收缩压及舒张压水平比较差异无统计学意义(P>0.05),干预后两组血压水平均改善,研究组收缩压及舒张压水平均低于对照组(P<0.05);干预前两组患者FMD及肱动脉直径比较差异无统计学意义(P>0.05),干预后两组患者上述指标水平均改善,研究组患者血管内皮功能水平高于对照组,研究组肱动脉直径大于对照组(P<0.05);研究组患者咳嗽、心率加快、头痛、直立性低血压等不良反应的总发生率为20.5%,对照组总发生率为23.1%,两组比较差异无统计学意义(P>0.05)。结论:对顽固性高血压患者施以缬沙坦联合特拉唑嗪方案治疗,可促进临床疗效提升,并能有效调节血压水平,还能改善血管内皮功能及肱动脉直径,且不会增加药物不良反应,值得应用。
Objective:To investigate the effect of Valsartan combined with Terazosin in the treatment of refractory hypertension.Method:A total of 78 patients with intractable hypertension in our hospital from March 2019 to December 2020 were selected,and the relevant clinical data were collected to carry out this study.They were grouped according to differences in drug use.Both of the two groups treated with routine treatment.The control group was treated with conventional therapy and Valsartan on this basis,while the study group was treated with Valsartan and Terazosin.The clinical effect,blood pressure,vascular endothelial function,brachial artery diameter and adverse reactions of the two groups were compared.Result:The total effective rate of the study group was higher than that of the control group(P<0.05);before intervention,the systolic and diastolic blood pressure levels of the two groups had no significant difference(P>0.05);after treatment,the blood pressure levels of the two groups were improved,and the systolic and diastolic blood pressure of the study group were lower than those of the control group(P<0.05);before intervention,there was no significant difference in FMD and brachial artery diameter between the two groups(P>0.05),the above indexes of the two groups were improved after intervention,and the level of vascular endothelial function of the study group was higher than that of the control group,and the brachial artery diameter of the study group was larger than that of the control group(P<0.05);the total incidence of cough,heart rate acceleration,headache and postural hypotension of the study group was 20.5%,and that of the control group was 23.1%,with no significant difference between the two groups(P>0.05).Conclusion:Valsartan combined with Terazosin in the treatment of patients with refractory hypertension can promote the clinical efficacy,effectively regulate blood pressure,improve vascular endothelial function and brachial artery diameter,and will not increase adverse drug reactions,so it is worthy o
作者
严承泽
谢日升
黄祖坚
YAN Chengze;XIE Risheng;HUANG Zujian(Yangchun Hospital of Traditional Chinese Medicine,Yangchun 529600,China;不详)
出处
《中外医学研究》
2021年第21期174-177,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
缬沙坦
特拉唑嗪
顽固性高血压
应用效果
血压水平
Valsartan
Terazosin
Refractory hypertension
Application effect
Blood pressure level
